ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements
Q-Line Biotech clarified a clerical error: its board meeting time is 4:15 PM, not 3:00 PM. The November 12, 2026 meeting will consider half-yearly financial results.
Q-Line Biotech Limited held its 16th Annual General Meeting on September 30, 2026. The meeting transacted ordinary and special business, including financial statement adoption and director re-appointments.
Q-Line Biotech has sent a letter to shareholders with bounced emails, providing links to the Annual Report and 16th AGM Notice, scheduled for September 30, 2026.
Q-Line Biotech Limited has submitted its Annual Report for the financial year 2025-26. The full document is accessible via the provided company website link.
Q-Line Biotech approved the Board's Report, notice for the 16th AGM, and re-appointment of two Whole Time Directors and the Cost Auditor.
Q-Line Biotech Limited has re-appointed M/s. P S P & Associates as Cost Auditors for a 12-month term.
Q-Line Biotech amended its license agreement with Boule Medical AB, Sweden. The revision includes a 25% reduction in license/royalty costs effective from July 2026.
Q-Line Biotech Limited filed its quarterly Reconciliation of Share Capital Audit Report, as required under SEBI Regulation 76, for the quarter ended June 30, 2026.
Q-Line Biotech Ltd reported revenue from operations of ₹197.9 Cr (-8.6% YoY) and net profit of ₹34.4 Cr (+290.9% YoY) for H2 FY26.
Q-Line Biotech has scheduled a Board Meeting on 17 June 2026 to consider audited FY2026 financial results. Investors should note the upcoming discussion of performance.